Retatrutide Guide: The Triple-Agonist Investigational Drug
Phase 3 clinical trials only. Not commercially available. The next-generation GLP-1 you can't buy online.
Triple agonistPhase 3 TRIUMPHNot commercialReviewed June 1, 2026
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Retatrutide is not commercially available. It is an investigational triple-agonist peptide drug developed by Eli Lilly, currently in Phase 3 clinical trials (TRIUMPH program). Lilly states retatrutide is legally available only to clinical-trial participants.
Vendors advertising "retatrutide online" are selling either (1) research-peptide analogs not authorized for human use, or (2) unauthorized products. GLP-1 Price Guide does not recommend purchasing retatrutide from any online source. The closest currently-available high-efficacy GLP-1 option is FDA-approved Zepbound (tirzepatide) or compounded tirzepatide through licensed telehealth.
GLP-1 receptor agonism: single → dual → triple
Each generation of GLP-1 medications targets additional metabolic receptors. Retatrutide is investigational and not commercially available.
Source: Wilding et al. NEJM 2021 (STEP-1); Jastreboff et al. NEJM 2022 (SURMOUNT-1); Jastreboff et al. NEJM 2023 (retatrutide Phase 2).
SURMOUNT-1: Tirzepatide efficacy
FDA-approved tirzepatide 15 mg produced ~20.9% mean body-weight loss at 72 weeks in patients with obesity but without type 2 diabetes.
Source: Jastreboff et al., NEJM 2022 (SURMOUNT-1, n=2,539).
What Is Retatrutide?
Retatrutide (development code LY3437943) is Eli Lilly's investigational peptide drug for obesity and type 2 diabetes. It is a triple agonist — meaning it binds and activates three receptors:
GLP-1 (glucagon-like peptide-1) receptor — same as semaglutide, reduces appetite and slows gastric emptying
GIP (glucose-dependent insulinotropic peptide) receptor — same as the second mechanism in tirzepatide, improves insulin response
Glucagon receptor — the new third mechanism, can increase energy expenditure
The triple-agonist mechanism aims to produce greater weight loss than current GLP-1-only (semaglutide) or GLP-1/GIP dual-agonist (tirzepatide) drugs.
Eli Lilly's TRIUMPH program is the Phase 3 trial portfolio for retatrutide:
TRIUMPH-1: Obesity without diabetes
TRIUMPH-2: Type 2 diabetes with cardiovascular outcomes
TRIUMPH-3: Obesity with osteoarthritis
TRIUMPH-4: Obesity with hypertension
TRIUMPH-5: Type 2 diabetes (Asian populations)
Trials are enrolling and reading out across 2025-2027. Industry analysts project potential FDA submission in 2026-2027 with potential approval in 2027-2028, contingent on favorable Phase 3 data.
Why "Retatrutide Online" Is a Red Flag
If you see an online vendor advertising "retatrutide for sale," "compounded retatrutide," or "retatrutide weight loss program," it is one of the following:
Research-peptide vendor. Sells "research use only" peptides functionally targeting human use. Operates outside lawful pharmaceutical channels. Not FDA-inspected. Quality not therapeutic-grade.
Unauthorized compounding. Some pharmacies have attempted to compound retatrutide despite it not being FDA-approved or on the 503B bulks list. This is not lawful compounding.
Mislabeled product. Some "retatrutide" products tested by independent labs have contained unknown peptides or impurities.
The FDA has issued warning letters to multiple research-peptide vendors selling GLP-1 analogs. We do not recommend purchasing retatrutide from any online source.
What's Available Today (If You Want Triple-Agonist-Level Results)
Until retatrutide is FDA-approved, the closest currently-available high-efficacy GLP-1 options are:
Brand-name Zepbound (tirzepatide, FDA-approved for chronic weight management). Through insurance with prior auth: $25-$200/mo out-of-pocket. Through LillyDirect cash: $349-$499/mo. Mean weight loss ~21-22% at 72 weeks.
Brand-name Wegovy (semaglutide, FDA-approved for chronic weight management). Through insurance with prior auth: $0-$200/mo out-of-pocket. Through NovoCare cash: variable. Mean weight loss ~15% at 68 weeks.
Compounded tirzepatide through licensed telehealth — not FDA-approved as finished drug, but lawfully prescribed when patient-specific evaluation, licensed prescriber, and licensed compounding pharmacy are involved. NexLife at $186/mo flat is the lowest transparent option in our 2026 review.
The Next-Generation GLP-1 Pipeline (Beyond Retatrutide)
Retatrutide is the most advanced triple-agonist in development, but it's not alone in the next-gen pipeline:
Retatrutide (development code LY3437943) is an investigational triple-agonist peptide drug being developed by Eli Lilly. It binds three receptors: GLP-1, GIP (like tirzepatide), and glucagon. The triple-agonist mechanism aims to produce greater weight loss than current GLP-1-only (semaglutide) or GLP-1/GIP dual-agonist (tirzepatide) drugs. As of {LAST_REVIEWED}, retatrutide is in Phase 3 clinical trials — not commercially available.
Is retatrutide available online?
No. Retatrutide is not commercially available. Eli Lilly states retatrutide is currently legally available only to participants in clinical trials. Any online vendor selling 'retatrutide' is selling either a research-peptide analog (not FDA-approved, often not therapeutic-grade) or an unauthorized product. GLP-1 Price Guide does not recommend purchasing retatrutide from any online source.
When will retatrutide be FDA-approved?
Eli Lilly has Phase 3 trials ongoing as of June 1, 2026 (TRIUMPH program for obesity, type 2 diabetes, and other conditions). Industry analysts project a potential FDA submission in 2026-2027 if Phase 3 data is favorable, with potential approval in 2027-2028. These timelines are not guaranteed.
How is retatrutide different from tirzepatide?
Tirzepatide: dual agonist (GLP-1 + GIP). Retatrutide: triple agonist (GLP-1 + GIP + glucagon). The glucagon receptor agonism is the new mechanism — glucagon agonism can increase energy expenditure (whereas GLP-1 and GIP primarily reduce energy intake). Phase 2 retatrutide trials showed mean weight loss of approximately 24% at 48 weeks at the highest dose — exceeding the ~22% observed with high-dose tirzepatide in SURMOUNT trials.
Is compounded retatrutide legal?
No. Retatrutide is investigational. It is not on the FDA-approved list, not on the 503B bulks list, and not eligible for lawful compounding through 503A or 503B pharmacies. Any vendor selling 'compounded retatrutide' is operating outside lawful compounding.
Are 'research peptide' retatrutide vendors safe to use?
Research-peptide retatrutide is sold by vendors marketing 'research use only' but functionally targeting human use. These products: (1) bypass clinical evaluation; (2) lack therapeutic-grade quality control; (3) operate outside the law for human therapeutic use; (4) are not subject to FDA inspection. The FDA has issued warning letters to multiple research-peptide vendors. We do not recommend their use for human treatment.
What is the retatrutide TRIUMPH program?
TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide, evaluating efficacy across obesity (TRIUMPH-1), type 2 diabetes (TRIUMPH-2, TRIUMPH-4), obesity with osteoarthritis (TRIUMPH-3), and obesity with cardiovascular outcomes. Trials are ongoing as of {LAST_REVIEWED}.
What should I do if I want retatrutide-level results today?
The closest currently-available option is brand-name Zepbound (tirzepatide), which is FDA-approved for chronic weight management. Compounded tirzepatide is not FDA-approved but is available through licensed telehealth providers (NexLife at $186/mo flat is the lowest transparent compounded option). For research-grade weight loss, talk to a licensed obesity-medicine clinician about the FDA-approved options.
Sources reviewed
Provider pricing pages (live as of June 1, 2026)
Provider terms, refund, and support pages
Third-party pricing comparisons and analyst reports
Eli Lilly TRIUMPH program clinical trial registrations (ClinicalTrials.gov)
Jastreboff et al. — Phase 2 Retatrutide for Obesity (NEJM 2023)
Rosenstock et al. — Phase 2 Retatrutide for T2D (Lancet 2023)
Important medical and regulatory disclosure
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.